VMRC-RCZ
759,00 CAD$*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Renseignements généraux
| Description | The VMRC-RCZ cell line is a human renal cell carcinoma (RCC) line established from a patient with clear cell type kidney cancer. It was derived to investigate the biological and genetic underpinnings of renal carcinogenesis, particularly with regard to chromosomal abnormalities and tumor progression. Cytogenetic analysis of VMRC-RCZ has revealed deletion of the short arm of chromosome 9, specifically within the 9p21-22 region. This deletion implicates the loss of key tumor suppressor genes such as CDKN2A, which is commonly associated with various malignancies and plays a role in cell cycle regulation. In broader cancer genome analyses, VMRC-RCZ has contributed to the mapping of homozygous deletions across multiple tumor types. These studies show that regions like 9p21 often exhibit structural instability in cancer cell lines, including VMRC-RCZ, suggesting that genomic deletions in this region may confer a selective growth advantage during tumor evolution. Additionally, VMRC-RCZ has been incorporated into high-resolution genomic profiling platforms for the systematic identification of cancer-related mutations and copy number alterations, making it a valuable model for studying RCC pathogenesis and for the exploration of potential therapeutic vulnerabilities in renal malignancies. |
|---|---|
| Organisme | Human |
| Tissu | Kidney |
| Maladie | Renal cell carcinoma |
| Site métastatique | Renal |
| Synonymes | VMRCRCZ, Virginia Mason Research Center-Renal Cancer Z |
Caractéristiques
| Âge | Age unspecified |
|---|---|
| Genre | Sex unspecified |
| Origine ethnique | Caucasian |
| Propriétés de croissance | Adherent |
Données réglementaires
| Référence | VMRC-RCZ (Cytion catalog number 305886) |
|---|---|
| Niveau de biosécurité | 1 |
| NCBI_Numéro d'identification fiscale | 9606 |
| Cellosaurus - Numéro d'enregistrement | CVCL_1791 |
Données biomoléculaires
| Profil mutationnel | Mutation: TP53, Simple, p.Asp48Valfs*74 (c.143_146del4), Heterozygous (Cosmic-CLP=909781), VHL, Simple, c.463+2T>C, Heterozygous, Note=Splice donor mutation (Cosmic-CLP=909781) |
|---|
Manipulation
| Milieu de culture | EMEM (MEM Eagle), w: 2 mM L-Glutamine, w: 2.2 g/L NaHCO3, w: EBSS (Cytion article number 820100a) |
|---|---|
| Suppléments | Supplement the medium with 10% FBS |
| Réactif de dissociation | Accutase |
| Rapport de fractionnement | A ratio of 1:6 is recommended. |
| Renouvellement des fluides | 2 to 3 times per week |
| Milieu de congélation | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Décongélation et culture des cellules |
|
| Atmosphère d'incubation | 37°C, 5% CO2, humidified atmosphere. |
| Conditions d'expédition | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Conditions d'entreposage | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Contrôle de la qualité et analyse moléculaire
| Stérilité | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificat d'analyse (CoA)
| Numéro de lot | Type de certificat | Date | Numéro de catalogue |
|---|---|---|---|
| 305886-041125 | Certificat d'analyse | 05. Dec. 2025 | 305886 |